Evidence map›Paper›PMID 31333801›Full record

ArticleJournal of Cancer2019

Qi Han, Jinlong Ma, Yan Gu, Huihui Song, Malika Kapadia, Yuka Imamura Kawasawa, Sinisa Dovat, Chunhua Song, Zheng Ge

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. The Function of E2A in B-Cell Development.Advances in experimental medicine and biology · 2024
    Review
  3. Article
  4. IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater?International journal of molecular sciences · 2023
    Review
  5. Article
  6. MiRAGDB: A Knowledgebase of RAG Regulators.Frontiers in immunology · 2022
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Qi HanDepartment of Hematology, Zhongda Hospital, Medical School of Southeast University, Institute of Hematology Southeast University,Nanjing 210009, China.
Jinlong MaDepartment of Hematology, Zhongda Hospital, Medical School of Southeast University, Institute of Hematology Southeast University,Nanjing 210009, China.
Yan GuDepartment of Hematology, Zhongda Hospital, Medical School of Southeast University, Institute of Hematology Southeast University,Nanjing 210009, China.
Huihui SongDepartment of Hematology, Zhongda Hospital, Medical School of Southeast University, Institute of Hematology Southeast University,Nanjing 210009, China.
Malika KapadiaDepartment of Pediatrics, Pennsylvania State University Medical College, Hershey, PA17033, USA.
Yuka Imamura KawasawaInternational Cooperative Leukemia Group and International Cooperative Laboratory of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Sinisa DovatInternational Cooperative Leukemia Group and International Cooperative Laboratory of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Chunhua SongInternational Cooperative Leukemia Group and International Cooperative Laboratory of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Zheng GeDepartment of Hematology, Zhongda Hospital, Medical School of Southeast University, Institute of Hematology Southeast University,Nanjing 210009, China.
Southeast University · CNPenn State Milton S. Hershey Medical Center · USPennsylvania State University · US

Funding

Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood LeukemiaR01CA209829 · NCI · LOMA LINDA UNIVERSITY · PI DOVAT, SINISA, DUERKSEN-HUGHES, PENELOPE J · 2016 to 2020
$2.0M
Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemiaR01CA213912 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI DOVAT, SINISA · 2017 to 2021
$1.8M
NCI NIH HHS R01 CA209829NCI NIH HHS R01 CA213912
6 · The paper itself

Abstract

The recombination mediated by recombination activating gene (RAG) is not only the dominant mutational process but also the predominant driver of oncogenic genomic rearrangement in acute lymphoblastic leukemia (ALL). It is further responsible for leukemic clonal evolution. In this study, significant

Indexed as

acute lymphoblastic leukemiaadultIKZF1RAG1

Identifiers

PMID31333801
PMCPMC6636280
OpenAlexW2951117603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.